Well-known pharmaceutical company AstraZeneca has announced the withdrawal of its COVID-19 vaccine, Vaxzewria, months after admitting “rare and dangerous side effects” from the vaccine.
According to the release, the injection was monitored for side effects of decreased blood vessels and blood platelet count.
The development comes as a company that makes a vaccine that causes thrombosis in rare cases of Thrombocytopenia Syndrome (TTS) is being sued by 50 victims and their relatives who died due to the aforementioned side effects.
So far, at least 81 deaths in the UK have been linked to the vaccine.
However, the company said it was “decreasing demand” that led to the decision to withdraw the vaccine.
The statement emphasized that the oversupply of the new vaccine has led to a decrease in demand for Vaxevria, which is no longer manufactured or supplied.
In addition, the manufacturer will withdraw the marketing license of Vaxzevria in Europe.
London-listed AstraZeneca has moved into respiratory syncytial virus vaccines and obesity drugs after growth slowed last year due to falling sales of its COVID-19 drug.
According to the company, more than 6.5 million lives were saved and more than 3 billion doses were provided worldwide in the first year of use alone, according to The Guardian.
AstraZeneca’s COVID-19 vaccine has been approved for use by the Pakistani government in an effort to prevent the pandemic from spreading rapidly in the country.
The vaccine consists of another virus that has been modified to have the gene to produce a protein from the coronavirus that causes SARS-CoV-2.
